GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Analyst Ratings
NASDAQ:GRCL - Nasdaq - US38406L1035 - ADR - Currency: USD
ChartMill assigns a Buy % Consensus number of 79% to GRCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.76. This target is 4.99% above the current price.
GRCL was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about GRCL.
In the previous month the buy percentage consensus was at a similar level.
GRCL was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-22 | Stifel | Downgrade | Buy -> Hold |
| 2023-12-27 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-12-27 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-26 | BTIG | Downgrade | Buy -> Neutral |
| 2023-12-26 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-11-27 | Evercore ISI Group | Initiate | Outperform |
| 2023-10-19 | Stifel | Initiate | Buy |
| 2023-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-30 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-29 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-13 | BTIG | Maintains | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-06 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-22 | Citigroup | Initiate | Buy |
| 2022-06-01 | Cantor Fitzgerald | Initiate | Overweight |